Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO The trading up | StocksNcash | investorshub | 10/03/2023 5:02:17 AM |
$OKYO The gaining | mfayman | investorshub | 10/03/2023 4:09:06 AM |
Price gaining | StocksNcash | investorshub | 10/03/2023 3:48:27 AM |
$OKYO MomentumIts now up | glenn1919 | investorshub | 10/03/2023 2:30:00 AM |
must see | Count Crypto | investorshub | 10/03/2023 1:36:21 AM |
$OKYO bears are running | StocksNcash | investorshub | 10/03/2023 12:07:12 AM |
great article | Boris the Spider | investorshub | 10/02/2023 11:53:22 PM |
$OKYO Found an interesting article | Boris the Spider | investorshub | 10/02/2023 11:16:12 PM |
Lets go go go go... Up up and away we go. | Boris the Spider | investorshub | 10/02/2023 10:03:10 PM |
$OKYO Have a look at this | StocksNcash | investorshub | 10/02/2023 9:02:38 PM |
$OKYO Looks pretty positive | mfayman | investorshub | 10/02/2023 6:55:23 PM |
$OKYO Price now | Anita Dump | investorshub | 10/02/2023 4:06:06 PM |
$OKYO great article | StocksNcash | investorshub | 10/02/2023 3:50:57 PM |
The trading | Sirpeter | investorshub | 10/02/2023 3:32:47 PM |
The gaining | Pisd | investorshub | 10/02/2023 2:42:12 PM |
Consolidating here under 2$ ready to smash thru | mfayman | investorshub | 10/02/2023 1:15:57 PM |
$OKYO short squeeze article | Count Crypto | investorshub | 10/02/2023 12:09:17 PM |
$OKYO should we be shorting? | Ryguy008 | investorshub | 10/02/2023 10:14:18 AM |
Found an interesting article | Pisd | investorshub | 10/02/2023 7:23:15 AM |
$OKYO under $2 https://investorshub.advfn.com/uimage/uploads/2023/10/2/ladfe | Monksdream | investorshub | 10/02/2023 7:20:01 AM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...